You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK):"妥洛特羅貼劑"首仿獲批上市
格隆匯 02-07 12:22

格隆匯2月7日丨中國生物製藥(01177.HK)宣佈,集團開發的「妥洛特羅貼劑」(商標名:德瑞妥)已獲得中國國家藥品監督管理局的上市批准,用於緩解支氣管哮喘、急性支氣管炎、慢性支氣管炎、肺氣腫等氣道阻塞性疾病所致的呼吸困難等症狀。這是首個獲批上市的國產氣道阻塞性疾病外用貼劑。

妥洛特羅貼劑作用於支氣管平滑肌的β2-受體,通過擴張支氣管,鬆弛氣管肌肉,起到改善肺功能,促進氣管纖毛運動及鎮咳的作用。與傳統哮喘治療藥物相比,妥洛特羅貼劑通過透皮給藥的方式實現全身給藥,避免了肝臟首過效應,減少對胃腸道的刺激,並能保持穩定的血藥濃度,從而更有效地控制哮喘症狀,為哮喘、急慢性支氣管炎、肺氣腫等氣道阻塞性疾病患者的長期治療提供了便利且安全的解決方案。

妥洛特羅貼劑的適應人羣廣泛,半歲及以上兒童即可使用。相較於口服、吸入製劑,妥洛特羅貼劑用藥簡單方便,解決了兒童給藥困難的問題,減少了因操作不當而導致的用藥錯誤。德瑞妥打破了進口藥物的壟斷,將極大的緩解國內兒童哮喘用藥的緊張局面。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account